QualityStocksNewsBreaks – Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA) Featured in Mizuho Securities Research Report
Satsuma Pharmaceuticals (NASDAQ: STSA) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Satsuma provided the long-awaited update on their STS101 development plans following the disappointing Phase 3 data from the EMERGE trial last fall. Based on a detailed review of the EMERGE data, the company has identified multiple factors that may have played a role in trial's failure. We maintain our Neutral rating as we review these findings in more detail, and assess the likelihood of STS101 succeeding in its next Phase 3 trial. However, we are encouraged by our initial…